R0404

Ramipril

Name: Ramipril
Brand: SIGMA

synthetic (organic), ≥98% (HPLC), Angiotensin converting enzyme (ACE) inhibitor., powder

Synonym(s):

Tritace, [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

Select a Size

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₃H₃₂N₂O₅

CAS Number:

87333-19-5

Molecular Weight:

416.51

UNSPSC Code:

12352200

PubChem Substance ID:

24724586

NACRES:

NA.77

MDL number:

MFCD00865775

Product Name

Ramipril, ≥98% (HPLC)

SMILES string

O=C(N1[C@](CCC2)([H])[C@]2([H])C[C@H]1C(O)=O)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3

InChI key

HDACQVRGBOVJII-JBDAPHQKSA-N

InChI

1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

biological source

synthetic (organic)

assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: ~18 mg/mL

originator

Sanofi Aventis

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS08

signalword

Danger

hcodes

H360FD

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Daniela Dunkler et al.

JAMA internal medicine, 173(18), 1682-1692 (2013-08-14)

Type 2 diabetes mellitus and associated chronic kidney disease (CKD) have become major public health problems. Little is known about the influence of diet on the incidence or progression of CKD among individuals with type 2 diabetes. To examine the

Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.

Guillaume Pare et al.

Pharmacogenetics and genomics, 23(9), 470-478 (2013-07-11)

The objective of this study was to identify genetic variants associated with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. We carried out a genome-wide association study in 175 individuals with ACE inhibitor-associated angioedema and 489 ACE inhibitor-exposed controls from Nashville (Tennessee) and

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.

Carla Zoja et al.

American journal of physiology. Renal physiology, 304(6), F808-F819 (2012-11-09)

Bardoxolone methyl is an antioxidant inflammation modulator acting through induction of Keap1-Nrf2 pathway. Results from a recent phase IIb clinical trial reported that bardoxolone methyl was associated with improvement in the estimated glomerular filtration rate in patients with advanced chronic

Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.

Joshua I Barzilay et al.

Clinical journal of the American Society of Nephrology : CJASN, 8(2), 233-240 (2012-11-28)

The microvascular circulation plays an important role in bone health. This study examines whether albuminuria, a marker of renal microvascular disease, is associated with incident hip and pelvic fractures. This study reanalyzed data from the Ongoing Telmisartan Alone and in

Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.

G Castoldi et al.

American journal of nephrology, 37(1), 65-73 (2013-01-19)

Diabetic nephropathy is the main cause of end-stage renal disease. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a physiological tetrapeptide hydrolyzed by the angiotensin-converting enzyme (ACE), has antifibrotic effects in the cardiovascular system and in the kidney in experimental models of hypertension, heart failure and

View All Related Papers